文献速递免疫规划

评估20价肺炎球菌结合疫苗在既往接种过不同肺炎球菌疫苗的≥65岁成人中的安全性和免疫原性的试验

A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination.
PubMed 文献 · Vaccine · 2021-11-25

这项3期、多中心、随机、开放标签研究在美国和瑞典开展,将≥65岁且有不同既往肺炎球菌疫苗接种史的成人按队列随机接种PCV20或对照疫苗。结果显示PCV20在各队列中安全性和免疫原性与对照疫苗相当,对20种疫苗血清型均产生稳健免疫应答。

要点

  • PCV20在既往接种PPSV23、PCV13或两者均接种的≥65岁成人中安全且免疫原性良好。
  • 各队列PCV20接种后局部反应、全身事件和不良事件百分比与PCV13和PPSV23对照组相当。
  • 无论既往肺炎球菌疫苗接种史如何,PCV20接种1个月后对20种疫苗血清型均观察到稳健免疫应答。

核心结论

  • PCV20在既往接种过不同肺炎球菌疫苗方案的≥65岁成人中耐受性良好且具有免疫原性。

研究设计与样本

  • 3期、多中心、随机、开放标签研究,在美国和瑞典开展,纳入≥65岁成人。
  • 参与者按既往肺炎球菌疫苗接种史(仅PPSV23、仅PCV13、PCV13和PPSV23均接种)分为3个队列。
  • 仅既往接种PPSV23者按2:1随机接受单剂PCV20或PCV13;仅既往接种PCV13者按2:1随机接受单剂PCV20或PPSV23;既往PCV13和PPSV23均接种者全部接受PCV20。

主要发现

  • PCV20接种后报告局部反应、全身事件和不良事件的参与者百分比在各队列间相似,且与PCV13和PPSV23对照组相当。
  • 所有组别中严重不良事件(SAE)和新诊断慢性疾病(NDCMC)发生率均低。
  • 无论既往肺炎球菌疫苗接种史如何,PCV20接种1个月后对20种疫苗血清型均观察到稳健免疫应答,包括调理吞噬抗体应答。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A 20-valent pneumococcal conjugate vaccine, PCV20, was developed to expand protection against vaccine-preventable pneumococcal disease. PCV20 contains the components of the 13-valent pneumococcal conjugate vaccine, PCV13, and includes capsular polysaccharide conjugates for 7 additional serotypes. Thus, PCV20 may cover those additional serotypes in individuals previously vaccinated with PCV13 or provide benefits of immunization with a conjugate vaccine to individuals previously immunized with a pneumococcal polysaccharide vaccine. This study described the safety and immunogenicity of PCV20 in adults ≥65 years of age with prior pneumococcal vaccination. METHODS: This phase 3, multicenter, randomized, open-label study was conducted in the United States and Sweden. Adults ≥65 years of age were enrolled into 1 of 3 cohorts based on their prior pneumococcal vaccination history (23-valent pneumococcal polysaccharide vaccine [PPSV23], PCV13, or both PCV13 and PPSV23). Participants were randomized 2:1 within their cohort to receive a single dose of PCV20 or PCV13 in those with prior PPSV23 only, and PCV20 or PPSV23 in those with prior PCV13 only; all participants with prior PCV13 and PPSV23 received PCV20. Safety was assessed by prompted local reactions within 10 days, systemic events within 7 days, adverse events (AEs) within 1 month, and serious AEs (SAEs) and newly diagnosed chronic medical conditions (NDCMCs) within 6 months after vaccination. Immune responses 1 month after PCV20 were assessed. RESULTS: The percentages of participants reporting local reactions, systemic events, and AEs after PCV20 administration were similar across cohorts and comparable with the PCV13 and PPSV23 control groups. SAE and NDCMC rates were low in all groups. Robust immune responses, including opsonophagocytic antibody responses, to the 20 vaccine serotypes were observed 1 month after PCV20 regardless of prior pneumococcal vaccination. CONCLUSIONS: PCV20 was well tolerated and immunogenic in adults ≥65 years of age previously vaccinated with different pneumococcal vaccine regimens. Clinicaltrials.gov NCT03835975.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination. Vaccine. 2021. PMID: 34839993. doi:10.1016/j.vaccine.2021.10.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。